Boston Scientific Corporation $BSX Shares Sold by Crystal Rock Capital Management

Crystal Rock Capital Management lessened its stake in Boston Scientific Corporation (NYSE:BSX) by 37.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,670 shares of the medical equipment provider’s stock after selling 17,575 shares during the quarter. Crystal Rock Capital Management’s holdings in Boston Scientific were worth $1,295,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of BSX. BlackRock Inc. acquired a new position in shares of Boston Scientific during the second quarter worth approximately $5,534,781,000. Primecap Management Co. CA acquired a new stake in shares of Boston Scientific in the second quarter valued at approximately $2,156,233,000. Jupiter Topco LLC acquired a new stake in shares of Boston Scientific in the second quarter valued at approximately $803,357,000. Bank of America Corp DE bought a new position in Boston Scientific in the 2nd quarter worth approximately $556,026,000. Finally, Legal & General Group Plc bought a new position in Boston Scientific in the 2nd quarter worth approximately $431,890,000. 89.07% of the stock is owned by institutional investors.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney purchased 186,240 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director David C. Habiger acquired 2,100 shares of Boston Scientific stock in a transaction that occurred on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director directly owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have acquired 189,522 shares of company stock worth $9,157,810. Company insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on BSX. Truist Financial reduced their price objective on Boston Scientific from $57.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, October 14th. Jefferies Financial Group downgraded Boston Scientific from a “buy” rating to a “hold” rating and dropped their target price for the stock from $60.00 to $46.00 in a research report on Wednesday. UBS Group cut their price target on Boston Scientific from $67.00 to $57.00 and set a “buy” rating on the stock in a research note on Thursday. Leerink Partners cut their price target on Boston Scientific from $55.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, Piper Sandler decreased their price target on Boston Scientific from $65.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $61.87.

Boston Scientific Price Performance

BSX opened at $42.69 on Friday. The company has a fifty day moving average price of $44.93 and a two-hundred day moving average price of $57.15. The firm has a market capitalization of $61.86 billion, a PE ratio of 18.09, a P/E/G ratio of 1.04 and a beta of 0.58. Boston Scientific Corporation has a 52 week low of $39.57 and a 52 week high of $105.65. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting analysts’ consensus estimates of $0.73. The business had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. Boston Scientific had a return on equity of 18.73% and a net margin of 16.62%. The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.75 earnings per share. As a group, analysts anticipate that Boston Scientific Corporation will post 3.18 earnings per share for the current year.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Third-quarter revenue increased 1.5% year over year to $5.138 billion, topping the $5.07 billion consensus estimate, while adjusted earnings of $0.73 per share matched expectations. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: Robert W. Baird raised its price target from $50 to $51 and maintained an “outperform” rating, while BTIG, UBS and Sanford C. Bernstein retained bullish ratings despite lowering their targets. Analysts revise forecasts after Q3 results
• Positive Sentiment: Management pointed to long-term growth initiatives, including Elite AF trial enrollment and FDA clearances for StoneSmart and SEISMIQ catheter technologies. Recent insider activity also showed purchases rather than sales, offering a modest confidence signal.
• Neutral Sentiment: Boston Scientific expects approximately 4.25% reported full-year 2026 sales growth, but forecast fourth-quarter reported and organic sales declines of 1% to 3%. Boston Scientific cuts view again after cyberattack
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by roughly $150 million and continues to affect operations, customer activity and the recovery timeline.
• Negative Sentiment: Management lowered full-year adjusted EPS guidance to $3.16-$3.18, below investor expectations, and warned that growth could remain broadly flat in 2027 as EP and WATCHMAN weakness, China pricing pressure and product-related challenges persist. BSX Q3 earnings call flags growth challenges
• Negative Sentiment: Analyst sentiment became more cautious: Oppenheimer downgraded BSX to “market perform,” JPMorgan moved to “neutral,” and multiple firms cut price targets, including Wells Fargo to $45 and Needham to $48.

Boston Scientific Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.